4-(4-methylpiperazine-1-yl methyl)-1H-indole | 1038988-57-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-(4-methylpiperazine-1-yl methyl)-1H-indole
• 英文别名: 4-[(4-methylpiperazin-1-yl)methyl]-1H-indole
• CAS: 1038988-57-6
• 化学式: C₁₄H₁₉N₃
• 分子量: 229.325
• InChiKey: JSSYDKPXRFBJSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  22.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-methylpiperazine-1-yl methyl)-1H-indole 在 N-溴代丁二酰亚胺(NBS) 、 sodium hydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 3-bromo-1-(1-naphthylsulfonyl)-4-(4-methylpiperazin-1-ylmethyl)-1H-indole
  参考文献：
  名称：

  Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N1-arylsulfonyl indole derivatives as 5-HT6 receptor ligands

  摘要：

  4-(Piperazin-1-yl methyl)-N-1-arylsulfonyl indole derivatives were designed and synthesized as 5-HT6 receptor (5-HT6R) ligands. The lead compound 6a, from this series shows potent in vitro binding affinity, good PK profile, no CYP liabilities and activity in animal models of cognition. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.057
• 作为产物：
  描述：

  2-甲基-3-硝基苯甲酸 在 lithium aluminium tetrahydride 、 氯化亚砜 、 一水合肼 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.5h， 生成 4-(4-methylpiperazine-1-yl methyl)-1H-indole
  参考文献：
  名称：

  Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N1-arylsulfonyl indole derivatives as 5-HT6 receptor ligands

  摘要：

  4-(Piperazin-1-yl methyl)-N-1-arylsulfonyl indole derivatives were designed and synthesized as 5-HT6 receptor (5-HT6R) ligands. The lead compound 6a, from this series shows potent in vitro binding affinity, good PK profile, no CYP liabilities and activity in animal models of cognition. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.057

文献信息

• Discovery and Optimization of Pyrimidone Indoline Amide PI3Kβ Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers
  作者：Victor Certal、Jean-Christophe Carry、Frank Halley、Angela Virone-Oddos、Fabienne Thompson、Bruno Filoche-Rommé、Youssef El-Ahmad、Andreas Karlsson、Véronique Charrier、Cécile Delorme、Alexey Rak、Pierre-Yves Abecassis、Céline Amara、Loïc Vincent、Hélène Bonnevaux、Jean-Paul Nicolas、Magali Mathieu、Thomas Bertrand、Jean-Pierre Marquette、Nadine Michot、Tsiala Benard、Marc-Antoine Perrin、Olivier Lemaitre、Stephane Guerif、Sébastien Perron、Sylvie Monget、Florence Gruss-Leleu、Gilles Doerflinger、Houlfa Guizani、Maurice Brollo、Laurence Delbarre、Luc Bertin、Patrick Richepin、Véronique Loyau、Carlos Garcia-Echeverria、Christoph Lengauer、Laurent Schio

  DOI：10.1021/jm401642q

  日期：2014.2.13

  Compelling molecular biology publications have reported the implication of phosphoinositide kinase PI3K beta in PTEN-deficient cell line growth and proliferation. These findings supported a scientific rationale for the development of PI3K beta-specific inhibitors for the treatment of PTEN-deficient cancers. This paper describes the discovery of 2-[2-(2,3-dihydro-indol-1-yl)-2-oxo-ethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one (7) and the optimization of this new series of active and selective pyrimidone indoline amide PI3K beta inhibitors. 2-[2-(2-Methyl-2,3-dihydro-indol-1-yl)-2-oxo-ethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one (28), identified following a carefully designed methyl scan, displayed improved physicochemical and in vitro pharmacokinetic properties. Structural biology efforts enabled the acquisition of the first X-ray cocrystal structure of p110 beta with the selective inhibitor compound 28 bound to the ATP site. The nonplanar binding mode described herein is consistent with observed structure-activity relationship for the series. Compound 28 demonstrated significant in vivo activity in a UACC-62 xenograft model in mice, warranting further preclinical investigation. Following successful development, compound 28 entered phase I/Ib clinical trial in patients with advanced cancer.
• WO2008/84491
  申请人：——

  公开号：——

  公开（公告）日：——